Rebuilding Sexual Function in Peyronie’s Disease: How Vacuum Therapy and Once-Daily Tadalafil Enhance Outcomes After Extracorporeal Shock Wave Treatment


Posted by admin on

Peyronie’s disease (PD) remains one of the most challenging conditions in sexual medicine. Defined by fibrotic plaque formation within the tunica albuginea, PD not only distorts the penile axis but also triggers pain, destabilizes erections, and disrupts intercourse. The disease’s impact extends far beyond anatomy: it erodes self-confidence, affects partners, and leads to profound psychosocial distress.

Despite its prevalence—up to 7% of men over 40—PD continues to lack an optimal, universally effective conservative therapy. Most treatments help a little, few help enough, and even fewer improve both curvature and erectile dysfunction (ED), which coexists in 40–60% of patients.

The study analyzed here offers an important contribution. For the first time, researchers evaluated whether a combined strategy consisting of:

  • extracorporeal shock wave therapy (ESWT),
  • daily tadalafil 5 mg, and
  • mechanical penile stretching via vacuum erection device (VED),

produces superior clinical outcomes compared with ESWT plus tadalafil alone.

Their results are striking: adding a VED significantly improves penile curvature, plaque remodeling, erectile function, and pain resolution—delivering an integrated, multimodal benefit unmatched by monotherapy.

This article synthesizes the full meaning of these findings and explores how they may reshape conservative PD management.

Understanding Peyronie’s Disease: A Fibrotic Condition With Vascular and Mechanical Consequences

PD is fundamentally a wound-healing disorder. Microtraumas to the erect penis—often repetitive and unnoticed—trigger an aberrant inflammatory response, resulting in collagen overproduction and fibrous plaque formation. The disease progresses through two stages:

  1. Active (inflammatory) stage — painful erections, evolving curvature, unstable plaque.
  2. Stable (chronic) stage — persistent deformity, less pain, established fibrotic plaque.

The present study focuses precisely on patients in the stable stage, where conservative measures seek not to prevent new damage but to remodel existing plaques and restore function.

Curvature, which averaged ~33° at baseline in both groups (Table 3), directly compromises penetration. ED, present in 61% of the VED group and 54% of the no-VED group, further complicates therapy because curvature and poor rigidity interact biomechanically.

Managing PD with concurrent ED requires therapies that address:

  • penile hemodynamics,
  • tissue elasticity,
  • plaque remodeling,
  • pain and inflammation.

A single modality rarely achieves all these aims.

Rationale for ESWT, PDE5 Inhibition, and Vacuum Therapy: Complementary Mechanisms

Before analyzing outcomes, it is essential to understand how each treatment contributes to penile tissue recovery.

Extracorporeal Shock Wave Therapy (ESWT)

ESWT applies focused acoustic waves to affected tissue, producing:

  • micro-cavitation,
  • mechanical disruption of dense collagen,
  • release of nitric oxide,
  • stimulation of angiogenic mediators such as VEGF,
  • enhanced neovascularization.

These biological effects can soften plaque and reduce pain. However, ESWT alone has shown mixed results, as demonstrated in multiple meta-analyses. It tends to relieve pain reliably but inconsistently improves curvature.

Once-Daily Tadalafil (5 mg)

Tadalafil has a long half-life (17.5 hours), allowing stable PDE5 inhibition and continuous elevation of cGMP—enhancing penile endothelial function. In PD, tadalafil is believed to:

  • reduce oxidative stress,
  • limit fibrotic remodeling,
  • improve cavernosal hemodynamics,
  • support sexual function even without curvature reversal.

Daily dosing is particularly valuable because it maintains consistent therapeutic levels.

Vacuum Erection Device (VED)

VEDs apply negative pressure, producing mechanical traction that stretches plaque tissue. Over time, traction forces cause:

  • collagen realignment,
  • increased matrix turnover,
  • improved tissue elasticity,
  • plaque softening and thinning.

This mechanism is similar to traction devices but easier to tolerate, making long-term adherence more feasible.

Combining ESWT + tadalafil + VED integrates biochemical, vascular, and mechanical effects—precisely the synergistic approach PD pathology requires.

Study Overview and Patient Cohorts

The study retrospectively analyzed 153 men with stable PD and concomitant ED treated between 2018 and 2023 at two Italian centers. Patients were divided into:

  • Group A (GA) — ESWT + VED + tadalafil 5 mg daily (n=72)
  • Group B (GB) — ESWT + tadalafil 5 mg daily only (n=81)

Key baseline similarities included age, disease duration, plaque size, plaque location, and curvature degree (Table 1). Importantly, both groups had comparable comorbidity profiles, including diabetes and hypertension.

Men with active PD, low testosterone, multiple plaques, or prior treatments were excluded to preserve homogeneity.

Follow-up assessments occurred at 3, 6, and 12 months, tracking:

  • penile curvature (goniometer after PGE-1 injection),
  • plaque size (ultrasound),
  • pain during erection (VAS),
  • erectile function (IIEF-15).

This time-scale is meaningful: PD remodeling requires months, not weeks, to manifest clinically detectable changes.

Penile Curvature: The Most Striking Improvement Comes From Adding VED

Curvature changes form the core of PD treatment goals. The study shows that while both groups experienced improvement, GA outperformed GB at every time point.

Numerical results (Table 3)

  • Baseline:
    • GA: 33.91°
    • GB: 32.64°
  • At 12 months:
    • GA: 19.46°
    • GB: 24.10°

The difference (≈5° additional reduction) is clinically meaningful—often the difference between painful failure and functional penetration.

Why does VED enhance curvature correction?

VED traction promotes gradual mechanical elongation of the shorter, fibrotic side of the tunica. ESWT softens plaques; tadalafil reduces fibrosis and supports healing; VED provides the daily stretching force needed to remodel tissue consistently.

This triad mirrors modern orthopedic approaches—biologic softening + traction—applied to tunical fibrosis.

Plaque Size Reduction: Only the Combined Therapy Achieves Significant Remodeling

At baseline, plaque sizes were almost identical between groups (~12 mm).

But at follow-up:

  • At 6 months:
    • GA: 7.22 mm
    • GB: 10.72 mm (p = 0.001)
  • At 12 months:
    • GA: 7.13 mm
    • GB: 10.68 mm (p = 0.001)

The ≈30–35% greater reduction in GA underscores the importance of traction in plaque remodeling. ESWT alone does not reliably shrink plaque volume; tadalafil may stabilize fibrosis but rarely reverses it. The VED appears to be the missing link that converts plaque softening into measurable reduction.

Pain Resolution: Excellent Outcomes in Both Groups, Faster in GA

Pain during erection is a hallmark of the inflammatory stage but can persist into the stable phase.

Both groups showed substantial pain relief:

  • GA: VAS reduced from 6.53 to 1.2
  • GB: VAS reduced from 6.63 to 1.3

Although differences were not statistically significant, GA achieved earlier and more uniform pain resolution.

This is consistent with ESWT’s strong and well-established analgesic effect.

Erectile Function: Combination Therapy Produces Superior Sexual Outcomes

Erectile function improvements are essential because many PD patients cannot penetrate not only due to curvature but also due to inadequate rigidity.

IIEF-15 outcomes

At baseline:

  • GA: 11.42
  • GB: 13.76

At 12 months:

  • GA: 17.44
  • GB: 15.13

These improvements translate to restoring mild-to-moderate ED to near-normal ranges in many cases.

Why does GA improve ED more?

  1. VED increases penile oxygenation, combating cavernosal fibrosis.
  2. Tadalafil improves endothelial function, supporting rigidity.
  3. ESWT enhances penile hemodynamics and NO release.
  4. Curvature reduction improves biomechanics, reducing buckling during intercourse.

The synergy restores erectile function more effectively than any single modality.

Functional outcomes

  • 88.9% of GA patients regained full intercourse ability, versus 60.5% in GB.
  • Only 2.8% of GA and 3.7% of GB required surgery—very low rates for stable PD.

These data indicate that combination therapy not only improves symptoms but often restores sexual function sufficiently to avoid procedures.

Why ESWT Alone Has Inconsistent Results—And Why Combining It Works

Several controlled trials have shown ESWT reliably reduces pain but inconsistently affects curvature or plaque size. The current study explains why:

  • ESWT mechanically disrupts the plaque but does not provide directional traction for remodeling.
  • Without prolonged mechanical guidance, softened plaques reorganize randomly, limiting curvature correction.
  • ESWT may stimulate angiogenesis, but without continuous hemodynamic support from PDE5 inhibition, benefits may fade.

Thus, ESWT prepares the plaque, tadalafil stabilizes, and VED reshapes.

This sequence reflects a biologically sound, multi-mechanism remodeling strategy.

Implications for Clinical Practice: A New Conservative Standard for PD With ED

The study advances a strong argument for transitioning from monotherapies to structured multimodal protocols for PD.

Key advantages of adding VED to ESWT + tadalafil:

  • significantly greater curvature improvement,
  • major plaque size reduction,
  • better erectile function recovery,
  • higher intercourse success rate,
  • excellent tolerability.

When to consider this combination

  • men in stable PD stage,
  • curvature <60°,
  • plaque <20 mm,
  • coexisting ED (mild to severe),
  • patients preferring non-surgical approaches.

The average follow-up of 14.6 months confirms long-term stability of results.

Study Limitations and Interpretation Cautions

The authors acknowledge several limitations:

  • retrospective design,
  • non-randomized grouping influenced by patients’ ability to afford VED,
  • slightly different baseline ED severity,
  • lack of long-term outcomes beyond 1 year.

Nevertheless, the consistency of improvements across multiple domains, the large sample size, and the mechanistic rationale strengthen the conclusions.

Conclusion: Multimodal Therapy Marks the Future of Peyronie’s Disease Management

This study provides strong evidence that VED + daily tadalafil significantly enhances the clinical effect of ESWT in men with PD and ED.

The multimodal approach:

  • remodels plaques more effectively,
  • reduces curvature to functionally meaningful levels,
  • restores erectile function in nearly 90% of patients,
  • relieves pain,
  • minimizes need for surgery.

These synergistic effects arise because each modality addresses a different layer of PD pathology: mechanical fibrosis, vascular dysfunction, and tunical remodeling.

The conclusion is clear: in stable Peyronie’s disease with erectile dysfunction, ESWT should not stand alone. The addition of a VED and daily tadalafil meaningfully improves patient outcomes and should be considered in modern PD management.

FAQ

1. Does adding a vacuum device actually change plaque structure or just stretch the penis?

VED therapy induces true tissue remodeling. By applying cyclic traction, it encourages collagen realignment and extracellular matrix turnover. In this study, plaque size decreased significantly only in the group using VED.

2. Why is tadalafil needed every day instead of on-demand?

Daily tadalafil supports endothelial function, increases penile blood flow, and reduces fibrosis progression. Its continuous vasodilatory effect complements the mechanical and biological changes induced by ESWT and VED.

3. Is ESWT enough without VED or PDE5 inhibitors?

ESWT alone reliably reduces pain but offers limited and inconsistent improvements in curvature and plaque size. The current data show that combining ESWT with VED and tadalafil produces significantly better outcomes.